BioNTechBNTX
BNTX
About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Employees: 6,772
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
39% more call options, than puts
Call options by funds: $373M | Put options by funds: $269M
27% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 49
10% more capital invested
Capital invested by funds: $5.25B [Q3] → $5.78B (+$535M) [Q4]
2.71% more ownership
Funds ownership: 18.63% [Q3] → 21.34% (+2.71%) [Q4]
1% more funds holding
Funds holding: 294 [Q3] → 297 (+3) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 7 (+0) [Q4]
2% less repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 85
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$139
39%
upside
Avg. target
$156
56%
upside
High target
$172
71%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Terence Flynn 42% 1-year accuracy 8 / 19 met price target | 39%upside $139 | Overweight Maintained | 11 Mar 2025 |
Canaccord Genuity John Newman 32% 1-year accuracy 9 / 28 met price target | 71%upside $171 | Buy Maintained | 11 Mar 2025 |
BMO Capital Etzer Darout 31% 1-year accuracy 11 / 36 met price target | 43%upside $143 | Outperform Maintained | 11 Mar 2025 |
Truist Securities Asthika Goonewardene 28% 1-year accuracy 7 / 25 met price target | 71%upside $172 | Buy Initiated | 10 Jan 2025 |
Financial journalist opinion
Based on 13 articles about BNTX published over the past 30 days
Neutral
Seeking Alpha
2 days ago
BioNTech SE (BNTX) Q4 2024 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX ) Q4 2024 Earnings Conference Call March 10, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder and Chief Executive Officer Ozlem Tureci - Co-Founder and Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Akash Tewari - Jefferies Chris Shibutani - Goldman Sachs Tazeen Ahmad - Bank of America Securities Terence Flynn - Morgan Stanley Harry Gillis - Berenberg Cory Kasimov - Evercore Sadia Rahman - Wells Fargo Asthika Goonewardene - Truist Securities Yaron Werber - TD Cowen Jessica Fye - JP Morgan Operator Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations.
Negative
Investopedia
2 days ago
BioNTech Stock Drops as Sales Outlook Disappoints
U.S.-listed shares of BioNTech (BNTX) lost ground Monday, as the COVID-19 vaccine maker's soft outlook for the year offset better-than-expected quarterly results.
Neutral
Benzinga
2 days ago
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
BioNTech SE BNTX on Monday reported fourth-quarter per-share earnings of 1.08 euros ($1.17), down from 1.88 euros reported a year ago compared to the consensus of 38 cents.
Positive
The Motley Fool
2 days ago
BioNTech Surpasses Q4 Revenue Estimates
Biopharmaceutical company BioNTech SE (BNTX -1.85%) reported fourth-quarter and full-year 2024 earnings on Monday, March 10, that topped analysts' consensus expectations. It reported revenue of 1.19 billion euros, ahead of estimates for 1.14 billion but down nearly 43% from the prior year's quarter.
Negative
Reuters
2 days ago
BioNTech guides for worse-than-expected 2025 revenue decline
German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ($1.85 billion) and 2.2 billion euros, prompting a decline in its share price.
Neutral
GlobeNewsWire
2 days ago
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 and mRNA cancer immunotherapies Multiple data readouts expected in 2025 and 2026 aimed at providing clinical proof of BioNTech's pipeline strategy and advancing the Company towards becoming a diversified multi-product oncology portfolio company by 2030 Completed acquisition of Biotheus securing full control of next-generation immunomodulator candidate BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1 Successfully launched JN.1- and KP.2-adapted COVID-19 vaccines across different countries and regions and maintained global market leadership Fourth quarter and full year 2024 revenues of €1.2 billion and €2.8 billion**, respectively Full year 2024 net loss of €0.7 billion and diluted loss per share of €2.77 ($3.00)1 Cash and cash equivalents plus security investments of €17.4 billion as of December 31, 2024 2 Expects 2025 total reven ues between €1.7 billion and €2.2 billion Conference call and webcast scheduled for March 10, 2025, at 8:00 a.m. EDT (1:00 p.m.
Neutral
Benzinga
5 days ago
BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
BioNTech SE BNTX will release its fourth-quarter financial results before the opening bell on Monday, March 10.
Negative
Reuters
1 week ago
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court in Duesseldorf on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna.
Negative
Reuters
1 week ago
U.S. FDA places clinical hold on BioNTech's malaria vaccine study
BioNTech said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an early-to-mid stage trial of its malaria vaccine.
Negative
Forbes
2 weeks ago
FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled
A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month.
Charts implemented using Lightweight Charts™